Literature DB >> 16878618

Rustom Jal Vakil: his contributions to cardiology.

Sumit Isharwal1, Shubham Gupta.   

Abstract

Rustom Jal Vakil returned to India in 1938 after earning his medical degree from the University of London and focused on the treatment of heart ailments at a time when cardiology was not a distinct subspecialty in India. In 1949, after years of scrupulous collation and analysis of data, he published a watershed paper on the antihypertensive properties of Rauwolfia serpentina and effected a paradigm shift in the management of hypertension. Rauwolfia was the world's 1st successful blood-pressure-lowering agent, and its acceptance encouraged research scientists to pursue the development of other hypotensive drugs. Vakil was a prolific researcher whose contributions to Indian cardiovascular epidemiology--and to the whole of medical literature--were enormous. He was also a fine clinician with a remarkable gift for communication, be it with his patients, students, peers, or the lay public. All of this came together to make him the embodiment of a medically competent India.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16878618      PMCID: PMC1524711     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  43 in total

1.  Ischaemic heart disease in India.

Authors:  R J VAKIL
Journal:  Br Heart J       Date:  1963-05

2.  Repetitive paroxysmal ventricular tachycardia with fusion beats.

Authors:  R J VAKIL
Journal:  Br Heart J       Date:  1957-04

3.  Rauwolfia serpentina in the treatment of high blood-pressure.

Authors:  R J VAKIL
Journal:  Lancet       Date:  1954-10-09       Impact factor: 79.321

4.  Preliminary observations of Rauwiloid-hexamethonium combined therapy of hypertension.

Authors:  R V FORD; J H MOYER
Journal:  Am Heart J       Date:  1953-11       Impact factor: 4.749

5.  On the constitution of reserpine.

Authors:  A FURLENMEIER; R LUCAS; H B MACPHILLAMY; J M MULLER; E SCHLITTLER
Journal:  Experientia       Date:  1953-09

6.  [Pharmacology of reserpin, a new alkaloid from Rauwolfia serpentina Benth].

Authors:  H J BEIN
Journal:  Experientia       Date:  1953-03-15

7.  The use of Rauwolfia serpentina in hypertensive patients.

Authors:  R W WILKINS; W E JUDSON
Journal:  N Engl J Med       Date:  1953-01-08       Impact factor: 91.245

Review 8.  When symptoms persist: choosing among alternative somatic treatments for schizophrenia.

Authors:  G W Christison; D G Kirch; R J Wyatt
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

9.  Use of Rauwolfia serpentina Benth. in neuropsychiatric conditions.

Authors:  N S KLINE
Journal:  Ann N Y Acad Sci       Date:  1954-04-30       Impact factor: 5.691

10.  Dr. Rustom Jal Vakil.

Authors:  B K Goyal
Journal:  Indian Heart J       Date:  1974-10
View more
  5 in total

1.  Comparative extrapyramidal effects of Rauwolfia vomitoria, chlorpromazine and reserpine in mice.

Authors:  Sunday Agba Bisong; Richard Earl Brown; Eme Effiom Osim
Journal:  J Nat Med       Date:  2012-03-30       Impact factor: 2.343

Review 2.  Rauwolfia in the Treatment of Hypertension.

Authors:  Douglas Lobay
Journal:  Integr Med (Encinitas)       Date:  2015-06

3.  Mutual learning and research messages: India, UK, and Europe.

Authors:  Gurvinder Kalra; Dinesh Bhugra
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

Review 4.  Revival, modernization and integration of Indian traditional herbal medicine in clinical practice: Importance, challenges and future.

Authors:  Saikat Sen; Raja Chakraborty
Journal:  J Tradit Complement Med       Date:  2016-06-28

5.  Continuous cropping of endangered therapeutic plants via electron beam soil-treatment and neutron tomography.

Authors:  Cheul Muu Sim; Bong Jae Seong; Dong Won Kim; Yong Bum Kim; Seung Gon Wi; Gyuil Kim; Hwasuk Oh; TaeJoo Kim; Byung Yeoup Chung; Jeong Young Song; Hong Gi Kim; Sang-Keun Oh; Young Dol Shin; Jea Hwan Seok; Min Young Kang; Yunhee Lee; Mabuti Jacob Radebe; Nikolay Kardjilov; Bernd Honermeier
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.